Stanbio Acquires GDS Technology

The company's international distribution network is established in more than 70 countries around the world. The acquisition will further expand Stanbio's original equipment manufacturer (OEM) capabilities. Stanbio will also benefit from the research partnerships GDS has formed to explore its proprietary enzyme technology, which include the U.S. National Institutes of Health and the U.S. Department of Defense.

"With the addition of GDS Technology, we can strengthen our clinical chemistry line, which remains our core business, and further expand our product offering to include point-of-care testing,” said William R. Pippin, present of Stanbio Laboratory. "In addition, the unique synergy between our two operations will create numerous business opportunities as we merge the businesses.”




Related Links:
Stanbio
GDS Technology